跳至主要内容

World Immunization Day – Since the immunity track has become popular, Medicilon will help you seize the 100 billion blue ocean market!

 


Strong Immune System


It is a solid “Shield” for human health

Immunity is the bodies’ own defense mechanism.  It is the human body’s self-protection ability to identify and eliminate any foreign matter (virus, bacteria, etc.) that invades from the outside, deal with aging, damaged, dead, and degenerated own cells, as well as identify and deal with mutant cells and virus-infected cells in the body, thereby maintaining the health of the human body.

The book “The Autoimmune Fix” mentions: 95% of human diseases are caused by low immunity. Immunity is increased by 30%, cancer incidence and infection rates are reduced by 50%, and people are 10 years younger.

This immune system is the solid “Shield” for human health.  Different people have different immune systems.  Age is not the only factor in the “aging” of the immune system.  Underweight or obesity, bad living habits, abnormal biochemical indicators, pregnancy and disease can all affect the immune system.

Low immunity will cause symptoms such as repeated colds, fatigue, and difficulty in wound healing. Long-term low immunity may even promote the occurrence and development of tumors.

When the immune system reacts beyond normal limits, it can cause harm to the body.  When the immune system is in chaos, immune cells cannot accurately identify “self” and “foreign body” and mistakenly attack normal and harmless cells, tissues, and organs in the body, which may lead to the occurrence of autoimmune disease (AID).  Therefore, maintaining immune balance can maintain human health.

148 Autoimmune Diseases

Huge unmet Clinical Needs

Colitis occurs when the immune system attacks its own colon; attacking the synovial membrane in joints, causing rheumatoid arthritis and spondylitis; attacking skin cells, causing psoriasis; attacking nerve tissue, causing damage to brain and spinal cord functions, causing allergic encephalomyelitis; attacking the beta cells responsible for producing insulin, causing type I diabetes; attacking melanocytes and causes vitiligo; attacking multiple systems, multiple tissues and organs, causing lupus erythematosus…

As of today, approximately 148 autoimmune diseases have been discovered in humans.  Statistics show that autoimmune diseases affect about 5% to 8% of the world’s population, and the number of patients is estimated to be more than 500 million; there are nearly 40 million patients with major autoimmune diseases in China.  From a treatment perspective, the pathogenesis of autoimmune diseases is complex and requires long-term medication.  Problems such as drug resistance and compliance are common and are called “immortal cancers” that often require upgrading. This promotes the continued development of the autoimmune disease drug.

List of autoimmune diseases by the American Autoimmune
Related Diseases Association (AARDA)

The order is based on the first letter of the English
name of the disease and has nothing to do with the incidence.

1.Achalasia

2.Addison’s disease

3.Adult Still’s disease

4.Agammaglobulinemia

5.Alopecia areata

6.Amyloidosis

7.Ankylosing spondylitis

8.Anti-GBM/Anti-TBMnephritis

9.Antiphos Pholipid Syndrome,APS

10.Autoimmune angioedema

11.Autoimmune dysautonomia

12.Autoimmune encephalomyelitis

13.Autoimmune hepatitis

14.Autoimmune inner ear disease,AIED

15.Autoimmune myocarditis

16.Autoimmune oophoritis

17.Autoimmune orchitis

18.Autoimmune pancreatitis

19.Autoimmune retinopathy

20.Autoimmune urticaria

21.Axonal &neuronal neuropathy,AMAN

22.Baló disease

23.Behcet’s disease

24.Benign mucosalpemphigoid

25.Bullous pemphigoid

26.Castleman disease,CD

27.Celiac disease

28.Chagas disease

29.Chronic inflammatory demyelinating polyneuropathy,CIDP

30.Chronicrecurrent multifocal osteomyelitis,CRMO

31.Churg-Strauss Syndrome,CSS

32.Cogan’s syndrome

33.Cold agglutinin disease

34.Congenitalheart block

35.Coxsackiemyocarditis

36.CREST syndrome

37.Crohn’s disease

38.Dermatitisher petiformis

39.Dermatomyositis

40.Devic’s disease

41.Discoid lupus

42.Dressler’s syndrome

43.Endometriosis

44.Eosinophilicesophagitis,EoE

45.Eosinophilicfasciitis

46.Erythemanodosum

47.Essentialmixed cryoglobulinemia

48.Evans syndrome

49.Fibromyalgia

50.Fibrosingalveolitis

51.Giant cellarteritis

52.Giant cellmyocarditis

53.Glomerulonephritis

54.Goodpasture’s syndrome

55.Granulomatosiswith Polyangiitis,GPA

56.Graves’ disease

57.Guillain-Barre Syndrome

58.Hashimoto’sthyroiditis

59.Hemolyticanemia

60.Henoch-Schonlein purpura,HSP

61.Herpesgestationis or pemphigoid gestationis

62.HidradenitisSuppurativa

63.Hypogammaglobulinemia

64.IgANephropathy

65.IgG4-relatedsclerosing disease

66.Immunethrombocytopenic purpura,ITP

67.Inclusionbody myositis,IBM

68.Interstitialcystitis,IC

69.Juvenilearthritis

70.Juvenile myositis

71.Kawasakidisease

72.Lambert-Eaton syndrome

73.Leukocytoclasticvasculitis

74.Lichen planus

75.Lichensclerosus

76.Ligneousconjunctivitis

77.Linear IgAdisease

78.Lyme disease chronic

79.Meniere’s disease

80.Microscopic polyangiitis

81.Mixed connective tissue disease

82.Mooren’s ulcer

83.Mucha-Habermann disease

84.MultifocalMotor Neuropathy

85.Multiple Sclerosis

86.Myastheniagravis

87.Myositis

88.Narcolepsy

89.Neonatal Lupus

90.Neutropenia

91.Ocularcicatricial pemphigoid

92.Opticneuritis

93.Palindromic rheumatism

94.PANDAS

95.Paraneoplastic cerebellar degeneration

96.Paroxysmalnocturnal hemoglobinuria

97.Parry Rombergsyndrome

98.Pars planitis

99.Parsonage-Turner syndrome

100.Pemphigus

101.Peripheral neuropathy

102.Perivenous encephalomyelitis

103.Pernicious anemia

104.POEMS syndrome

105.Polyarteritis nodosa

106.Polyglandularsyndromes type I, II, III

107.Polymyalgiarheumatica

108.Polymyositis

109.Postmyocardialinfarction syndrome

110.Postpericardiotomy syndrome

111.Primarybiliary cirrhosis

112.Primary sclerosing cholangitis

113.Progesteronedermatitis

114.Psoriasis

115.Psoriatic arthritis

116.Pure red cell aplasia

117.Pyoderma gangrenosum

118.Raynaud’s phenomenon

119.Reactive Arthritis

120.Reflexsympathetic dystrophy

121.Relapsingpoly chondritis

122.Restless legs syndrome

123.Retroperitoneal fibrosis

124.Rheumatic fever

125.Rheumatoid arthritis,RA

126.Sarcoidosis

127.Schmidt syndrome

128.Scleritis

129.Scleroderma

130.Sjögren’s syndrome,SS

131.Sperm &testicular autoimmunity

132.Stiff person syndrome

133.Subacutebacterial endocarditis

134.Susac’s syndrome

135.Sympathetic ophthalmia

136.Systemic  Lupus Erythematosus,SLE

137.Takayasu’s arteritis

138.Temporalar teritis

139.Thyroid eyedisease,Ted

140.Tolosa-Hunt syndrome,THS

141.Type 1 diabetes,TIDM

142.Ulcerative colitis,UC

143.Undifferentiated connective tissue disease,UCTD

144.Uveitis

145.Vasculitis

146.Vitiligo

147.Vogt-Koyanagi-HaradaDisease

148Warm autoimmune hemolytic anemia

The world's autoimmune disease drug

Autoimmune diseases have long occupied the second largest disease market after cancer globally.  The global autoimmune disease drug market size will be approximately US$131.7 billion in 2022.  Among them, 7 drugs account for global sales of more than 5 billion US dollars and are super blockbusters.  According to Frost & Sullivan, the global market size is expected to reach US$176.7 billion by 2030.  The market size of China’s autoimmune disease drugs is approximately US$3.6 billion, which is less than the global sales of one product, Secukinumab, in one year.

The market size of China's autoimmune disease drugs

According to data from the National Health Commission, the current number of autoimmune diseases in China is approximately 80 million.  This huge patient group gives China’s autoimmune disease drug market huge potential, and also attracts big pharma and biotech to compete for investment.

Immune Disease Drug Efficacy Evaluation Model Platform

Medicilon empowers customers to leverage the market

The commercialization between local companies and giants will gradually become fiercer, autoimmune disease targets will be iterated at an accelerated pace, and new mechanism therapies will carry forward the past. How can we compete for supremacy in the future?  As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon has established an autoimmune disease drug efficacy evaluation model platform to empower partners to enter the 100 billion autoimmune disease drug markets.

Rheumatoid Arthritis

When the body’s immune system is overly strong, it will secrete many inflammatory factors, among which rheumatoid factors will attack the immunoglobulin IgG in the body to form immune complexes and cause inflammation.  In the early stage of the disease, local joint stiffness and pain appear, which gradually invade the whole body, and finally lead to joint loss of function and disability throughout the body.

Medicilon models that you can choose from:

  • CIA mice/rats Models
  • CFA rats Models
Major Endpoints:
(1) Foot Volume

Foot Volume of CIA Models & CFA Models 

(2) Arthritis Index
Arthritis Index-CIA Models
Arthritis Index-CIA Models
(3) Cytokine Expression
CFA Models
CFA Models
 
Other arthritis models:
  • Carrageenan-induced acute arthritis mice/rats models
  • Uric acid sodium induced gouty arthritis rats models

EAE, experimental allergic encephalomyelitis

Day after immunization: Body weight of the EAE models in male C57BL/6 mice & Clinical score of EAE models in C57BL/6 mice.

Psoriasis

Psoriasis is a common skin disease worldwide. It is a disease that is not only closely related to genetics, but also obviously related to the environment. Its pathogenic mechanism is not yet clear.

Medicilon has established diverse models that captures key features of psoriasis, including:

  • IL-23 induced hyperplasia of auricle epidermis mice
  • Imiquimod induced psoriasis mice
  • Vaginal epithelial mitosis mice
  • Tale exfoliation mice
Major Endpoints:
(1) Skin thickness
Pathological skin change of Imiquimod induced psoriasis mice
Pathological skin change of Imiquimod induced psoriasis mice
(2) Ear thickness
Pathological skin change of IL-23 induced psoriasis mice
Pathological skin change of IL-23 induced psoriasis mice
(3) Skin colligation score of mice
Pathological skin change of Imiquimod induced psoriasis mice
Pathological skin change of Imiquimod induced psoriasis mice
(4) Pathological skin score
Imiquimod induced psoriasis & △IL-23 induced psoriasis
Imiquimod induced psoriasis & IL-23 induced psoriasis

Pathological skin score

Atopic Dermatitis (AD)

Atopic dermatitis is a chronic, recurring, inflammatory skin disease, often accompanied by other symptoms such as allergic rhinitis, asthma, eczema, etc. The cause of the disease is not yet clear and there is no cure.

The disease related models include:

  • DNFB induced chronic dermatitis mice
  • DNFB & OX induced chronic dermatitis mice
  • Phorbol ester induced acute eczema mice
  • DNFB induced acute eczema mice

Skin score

DNFB induced chronic dermatitis
DNFB induced chronic dermatitis

Skin thickness

DNFB induced chronic dermatitis
DNFB induced chronic dermatitis

Skin thickness

IBD, Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a group of unexplained chronic intestinal inflammatory diseases. Due to the increasing incidence, it has become a common digestive system disease and is refered to as ulcerative colitis and Crohn’s Disease.

Our IBD models includes:

  • TNBS induced IBD rats
  • DSS induced IBD mice

IBD models

Colon length of TNBS induced IBD rats models
Colon length of TNBS induced IBD rats models
Colon weight of DSS induced IBD mice models
Colon weight of DSS induced IBD mice models

With the successive research and development of innovative drug mechanisms targeting inflammatory factors, Th17/treg balance, blocking Th2 pathways, and targeting B cells, the emergence of new immunotherapies is driving the continued development of the autoimmune disease drug.  In the future, Medicilon looks forward to the launch of more domestically produced innovative drugs with new targets and new mechanisms, which will assist the research and development of drugs for autoimmune diseases and contribute to the future of human health.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati